A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2029

Conditions

Prostate Cancer

Interventions

DRUG

REGN5678

Given by IV infusion

DRUG

Cemiplimab

Given by IV infusion

Trial Locations (1)

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER